Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7831-7840 Newer>

Chemistry World August 25, 2011 Fiona McKenzie	Poking Aspirin with a Sharp Stick Scientists have found a way to go one better than x-ray crystallography to examine pharmaceutical crystals at an even deeper level.
The Motley Fool August 25, 2011 Rich Smith	Patterson Companies' Shares Got Crushed: What You Need to Know Shares of dental and veterinary equipment supplier Patterson Companies are looking snake-bit today, down 11% as of this writing.
The Motley Fool August 25, 2011 Jim Royal	Does CR Bard Earn Its Keep? CR Bard has not seen significant changes in its returns on invested capital over the past five years, which suggests that it is effectively maintaining its competitive position.
The Motley Fool August 24, 2011 Brian Orelli	Can Roche and Merck Succeed Where Pfizer Failed? CETP inhibitors are lucrative but risky.
The Motley Fool August 24, 2011 Andrew Tonner	Does Bristol-Myers Squibb Look Like a Winning Investment? Bristol-Myers, Pfizer, and J&J all look tempting, trading in the mid-teens relative to their earnings.
The Motley Fool August 24, 2011 Andrew Tonner	Does Abbott Laboratories Look Like a Winning Investment? A quick check of their numbers shows us that Abbott Labs looks reasonably attractive.
The Motley Fool August 24, 2011 Brian Orelli	Growth, but Not Great Growth Medtronic's growth comes with lower margins.
The Motley Fool August 24, 2011 Brian D. Pacampara	United Therapeutics Shares Got Crushed: What You Need to Know Shares of drugmaker United Therapeutics plunged 17% today after its experimental orally administered lung drug failed in a late-stage clinical trial.
The Motley Fool August 24, 2011 Arundhati Parmar	Growth Is the Deity Medtronic CEO Omar Ishrak Will Worship CEO Omar Ishrak repeatedly said that a singular focus on growth would be his top priority to transform the company.
The Motley Fool August 24, 2011 Brandon Glenn	Cardinal Health Sees Opportunity (but Faces Challenges) in Specialty Drugs Is Cardinal up for the challenge?
<Older 7831-7840 Newer> Return to current articles.